Bruton's Tyrosine Kinase Inhibition As an Emerging Therapy in Systemic Autoimmune Disease

Overview

Journal Drugs

Specialty Pharmacology

Date 2021 Oct 5

PMID 34609725

Citations 21

Authors

Stefan F H Neys

Jasper Rip

Rudi W Hendriks

Odilia B J Corneth

Affiliations

Soon will be listed here.

Abstract

Systemic autoimmune disorders are complex heterogeneous chronic diseases involving many different immune cells. A significant proportion of patients respond poorly to therapy. In addition, the high burden of adverse effects caused by "classical" anti-rheumatic or immune modulatory drugs provides a need to develop more specific therapies that are better tolerated. Bruton's tyrosine kinase (BTK) is a crucial signaling protein that directly links B-cell receptor (BCR) signals to B-cell activation, proliferation, and survival. BTK is not only expressed in B cells but also in myeloid cells, and is involved in many different signaling pathways that drive autoimmunity. This makes BTK an interesting therapeutic target in the treatment of autoimmune diseases. The past decade has seen the emergence of first-line BTK small-molecule inhibitors with great efficacy in the treatment of B-cell malignancies, but with unfavorable safety profiles for use in autoimmunity due to off-target effects. The development of second-generation BTK inhibitors with superior BTK specificity has facilitated the investigation of their efficacy in clinical trials with autoimmune patients. In this review, we discuss the role of BTK in key signaling pathways involved in autoimmunity and provide an overview of the different inhibitors that are currently being investigated in clinical trials of systemic autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, as well as available results from completed trials.

Citing Articles

PGRN Inhibits Early B-cell Activation and IgE Production Through the IFITM3-STAT1 Signaling Pathway in Asthma.

Zhang P, Ruan C, Yang G, Guan Y, Zhu Y, Li Q Adv Sci (Weinh). 2024; 11(45):e2403939.

PMID: 39412083 PMC: 11615816. DOI: 10.1002/advs.202403939.

Nanoparticle-neutrophils interactions for autoimmune regulation.

Kupor D, Felder M, Kodikalla S, Chu X, Eniola-Adefeso O Adv Drug Deliv Rev. 2024; 209:115316.

PMID: 38663550 PMC: 11246615. DOI: 10.1016/j.addr.2024.115316.

Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.

Nuesslein-Hildesheim B, Ferrero E, Schmid C, Huck C, Smith P, Tisserand S J Neuroinflammation. 2023; 20(1):194.

PMID: 37633912 PMC: 10463946. DOI: 10.1186/s12974-023-02877-9.

Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation.

Li W, Zhu S, Liu J, Liu Z, Zhou H, Zhang Q Molecules. 2023; 28(16).

PMID: 37630287 PMC: 10458081. DOI: 10.3390/molecules28166035.

A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects.

Zhu L, Shi R, Zhao T, Ye Y, Tang J, Hu Y Clin Transl Sci. 2023; 16(10):1982-1996.

PMID: 37551782 PMC: 10582678. DOI: 10.1111/cts.13606.

References

Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y . Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 2018; 38(11):1802-1814. DOI: 10.1038/s41388-018-0550-3. View

Martin E, Aigrot M, Grenningloh R, Stankoff B, Lubetzki C, Boschert U . Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast. 2020; 5(2):123-133. PMC: 7685672. DOI: 10.3233/BPL-200100. View

Corneth O, Verstappen G, Paulissen S, de Bruijn M, Rip J, Lukkes M . Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. Arthritis Rheumatol. 2017; 69(6):1313-1324. DOI: 10.1002/art.40059. View

Genovese M, Spindler A, Sagawa A, Park W, Dudek A, Kivitz A . Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. J Rheumatol. 2020; 48(7):969-976. DOI: 10.3899/jrheum.200893. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Oldham A, Miner C, Wang H, Webb C . The transcription factor Bright plays a role in marginal zone B lymphocyte development and autoantibody production. Mol Immunol. 2011; 49(1-2):367-79. PMC: 3205293. DOI: 10.1016/j.molimm.2011.09.008. View

Engels N, Konig L, Schulze W, Radtke D, Vanshylla K, Lutz J . The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. Nat Commun. 2014; 5:5456. PMC: 4263166. DOI: 10.1038/ncomms6456. View

Hoepel W, Chen H, Geyer C, Allahverdiyeva S, Manz X, de Taeye S . High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. 2021; 13(596). PMC: 8158960. DOI: 10.1126/scitranslmed.abf8654. View

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

10.

Volmering S, Block H, Boras M, Lowell C, Zarbock A . The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation. Immunity. 2016; 44(1):73-87. PMC: 5030078. DOI: 10.1016/j.immuni.2015.11.011. View

11.

Evans E, Tester R, Aslanian S, Karp R, Sheets M, Labenski M . Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013; 346(2):219-28. DOI: 10.1124/jpet.113.203489. View

12.

Stadanlick J, Kaileh M, Karnell F, Scholz J, Miller J, Quinn 3rd W . Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol. 2008; 9(12):1379-87. PMC: 2744141. DOI: 10.1038/ni.1666. View

13.

Hartkamp L, Fine J, van Es I, Tang M, Smith M, Woods J . Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis. 2014; 74(8):1603-11. DOI: 10.1136/annrheumdis-2013-204143. View

14.

Kil L, de Bruijn M, van Nimwegen M, Corneth O, van Hamburg J, Dingjan G . Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012; 119(16):3744-56. DOI: 10.1182/blood-2011-12-397919. View

15.

Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291. PMC: 8151619. DOI: 10.1016/S0140-6736(20)30262-2. View

16.

Rip J, van der Ploeg E, Hendriks R, Corneth O . The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. Crit Rev Immunol. 2018; 38(1):17-62. DOI: 10.1615/CritRevImmunol.2018025184. View

17.

Ward J, James J, Zhao Y, Webb C . Antibody Reactivity of B Cells in Lupus Patients with Increased Disease Activity and ARID3a Expression. Antibodies (Basel). 2017; 4:354-368. PMC: 5451160. DOI: 10.3390/antib4040354. View

18.

Gui F, Jiang J, He Z, Li L, Li Y, Deng Z . A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies. Br J Pharmacol. 2019; 176(23):4491-4509. PMC: 6932946. DOI: 10.1111/bph.14809. View

19.

Park J, Byun J, Park J, Kim Y, Lee Y, Oh J . HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther. 2016; 18:91. PMC: 4835877. DOI: 10.1186/s13075-016-0988-z. View

20.

Roskoski Jr R . Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2015; 103:26-48. DOI: 10.1016/j.phrs.2015.10.021. View